{"@type": "dcat:Dataset", "accessLevel": "public", "accrualPeriodicity": "R/P1Y", "bureauCode": ["009:10"], "contactPoint": {"@type": "vcard:Contact", "fn": "Division of Drug Information", "hasEmail": "mailto:druginfo@fda.hhs.gov"}, "description": "CABOMETYX is a prescription medication containing cabozantinib, a kinase inhibitor that helps treat certain advanced cancers. It comes as oral tablets in strengths of 20 mg, 40 mg, and 60 mg, manufactured by Exelixis, Inc. This information was generated using AI and is provided for informational and research purposes only.", "distribution": [{"@type": "dcat:Distribution", "description": "\n        Access the FDA dataset for Cabozantinib \u2014 ANDA 208692 submitted by Mylan Institutional LLC\n    ", "downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208692", "mediaType": "text/html", "title": "Cabozantinib"}], "identifier": "ANDA208692", "issued": "2016-09-16", "keyword": ["drug-information", "health-care", "pharmaceuticals", "prescription-drugs", "public-health"], "landingPage": "https://www.fda.gov/drugs", "license": "https://open.fda.gov/license", "modified": "2025-03-17", "programCode": ["009:002"], "publisher": {"@type": "org:Organization", "name": "U.S. Food and Drug Administration"}, "theme": ["FDA"], "title": "Cabozantinib"}